Press release content from PR Newswire. The AP news staff was not involved in its creation. Exogenesis nanoMesh™ LLC (a subsidiary of Exogenesis Corporation) Announces Completion Of Production Validation For Exogenesis nanoMesh™ January 26, 2021 GMT BILLERICA, Mass., Jan. 26, 2021 /PRNewswire/ -- Exogenesis nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today the completion of production validation and sterilization validation as an immediate prelude to commercialization of Exogenesis nanoMesh™. The company anticipates first-in-man deployment of Exogenesis nanoMesh™ during the first quarter of 2021, followed immediately thereafter by national distribution. Exogenesis nanoMesh™ is an innovative soft tissue repair implant. Exogenesis nanoMesh™ possesses a unique nanometer-level surface texture, via the application of Accelerated Neutral Atom Beam (ANAB) technology1 during manufacturing. Exogenesis nanoMesh™ is indicated for the repair of abdominal wall hernias and abdominal wall deficiencies that require the addition of reinforcing material to obtain the desired surgical result. Exogenesis nanoMesh™ is expected to be commercially available throughout the US2 during 2021.